Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Decreased miR-218-5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer.

Peng P, Chen T, Wang Q, Zhang Y, Zheng F, Huang S, Tang Y, Yang C, Ding W, Ren D, Huang Z, Guo Y.

Oncol Res Treat. 2019 Mar 14:1-13. doi: 10.1159/000495473. [Epub ahead of print]

PMID:
30870834
2.

Nuclear receptors: recent drug discovery for cancer therapies.

Zhao L, Zhou S, Gustafsson JÅ.

Endocr Rev. 2019 Mar 14. pii: er.2018-00222. doi: 10.1210/er.2018-00222. [Epub ahead of print]

PMID:
30869771
3.

[PSA-based prostate cancer screening, a slippery slope].

Legoupil C, Hill C.

Rev Prat. 2018 Oct;68(8):832-838. French. No abstract available.

PMID:
30869445
4.

[Treatment of metastatic prostate cancer: what recent progress?]

Oudard S, Velev M, Belhadj Y, Vano Y, Thibault C.

Rev Prat. 2018 Sep;68(7):707-712. French. No abstract available.

PMID:
30869315
5.

The influence of patient case mix on public health area statistics for cancer stage at diagnosis: a cross-sectional study.

Barclay ME, Abel GA, Elliss-Brookes L, Greenberg DC, Lyratzopoulos G.

Eur J Public Health. 2019 Mar 14. pii: ckz024. doi: 10.1093/eurpub/ckz024. [Epub ahead of print]

PMID:
30869123
6.

The impact of warmed and humidified CO2 insufflation during robotic radical prostatectomy: Results of a randomized controlled trial.

Oderda M, Cerutti E, Gontero P, Manetta T, Mengozzi G, Meyer N, Munegato S, Noll E, Rampa P, Piéchaud T, Diemunsch P.

Urologia. 2019 Mar 14:391560319834837. doi: 10.1177/0391560319834837. [Epub ahead of print]

PMID:
30868938
7.

miR-493 Promotes Prostate Cancer Cells Proliferation by Targeting PHLPP2 and Activating Akt Signaling Pathway.

Deng J, Ma M, Jiang W, Zhang H, Cui S.

Clin Lab. 2019 Mar 1;65(3). doi: 10.7754/Clin.Lab.2018.180806.

PMID:
30868840
8.

Prostate Cancer Metastasis To Cervical Node Chain-An Unusual Clinic-Pathological Finding.

Iftikhar H, Ikram M, Iqbal MU, Ghaloo SK.

J Ayub Med Coll Abbottabad. 2019 Jan-Mar;31(1):134-135.

9.

Incidentally Found Metastatic Prostatic Carcinoma In A Therapeutic Orchiectomy Specimen.

Bilal M, Uddin Z, Khan MA.

J Ayub Med Coll Abbottabad. 2019 Jan-Mar;31(1):129-130.

10.

lncRNA PCAT19 promotes the proliferation of laryngocarcinoma cells via modulation of the miR-182/PDK4 axis.

Xu S, Guo J, Zhang W.

J Cell Biochem. 2019 Mar 13. doi: 10.1002/jcb.28552. [Epub ahead of print]

PMID:
30868666
11.

The Genus Solanum: An Ethnopharmacological, Phytochemical and Biological Properties Review.

Kaunda JS, Zhang YJ.

Nat Prod Bioprospect. 2019 Mar 12. doi: 10.1007/s13659-019-0201-6. [Epub ahead of print] Review.

PMID:
30868423
12.

Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?

Bruni A, Ingrosso G, Trippa F, Di Staso M, Lanfranchi B, Rubino L, Parente S, Frassinelli L, Maranzano E, Santoni R, Sighinolfi MC, Lohr F, Mazzeo E.

Clin Transl Oncol. 2019 Mar 13. doi: 10.1007/s12094-019-02084-0. [Epub ahead of print]

PMID:
30868389
13.

Added value of diffusion-weighted MRI for nodal radiotherapy planning in pelvic malignancies.

Sushentsev N, Martin H, Rimmer Y, Barrett T.

Clin Transl Oncol. 2019 Mar 13. doi: 10.1007/s12094-019-02068-0. [Epub ahead of print]

PMID:
30868387
14.

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions.

Schoots IG, Roobol MJ.

World J Urol. 2019 Mar 13. doi: 10.1007/s00345-019-02707-9. [Epub ahead of print]

PMID:
30868240
15.

The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men.

Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M.

Cancer Chemother Pharmacol. 2019 Mar 13. doi: 10.1007/s00280-019-03811-8. [Epub ahead of print]

PMID:
30868236
16.

Development of a microfluidic platform for size-based hydrodynamic enrichment and PSMA-targeted immunomagnetic isolation of circulating tumour cells in prostate cancer.

Esmaeilsabzali H, Payer RTM, Guo Y, Cox ME, Parameswaran AM, Beischlag TV, Park EJ.

Biomicrofluidics. 2019 Feb 8;13(1):014110. doi: 10.1063/1.5064473. eCollection 2019 Jan.

PMID:
30867880
17.

Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.

Shi SJ, Wang LJ, Han DH, Wu JH, Jiao D, Zhang KL, Chen JW, Li Y, Yang F, Zhang JL, Zheng GX, Yang AG, Zhao AZ, Qin WJ, Wen WH.

Theranostics. 2019 Feb 7;9(5):1247-1263. doi: 10.7150/thno.29884. eCollection 2019.

18.

ZFP91 zinc finger protein expression pattern in normal tissues and cancers.

Paschke L, Jopek K, Szyszka M, Tyczewska M, Malendowicz LK, Rucinski M.

Oncol Lett. 2019 Mar;17(3):3599-3606. doi: 10.3892/ol.2019.9963. Epub 2019 Jan 23.

19.

MicroRNA-1291 mediates cell proliferation and tumorigenesis by downregulating MED1 in prostate cancer.

Cai Q, Zhao A, Ren L, Chen J, Liao K, Wang Z, Zhang W.

Oncol Lett. 2019 Mar;17(3):3253-3260. doi: 10.3892/ol.2019.9980. Epub 2019 Jan 28.

20.

Induction of entosis in prostate cancer cells by nintedanib and its therapeutic implications.

Liu J, Wang L, Zhang Y, Li S, Sun F, Wang G, Yang T, Wei D, Guo L, Xiao H.

Oncol Lett. 2019 Mar;17(3):3151-3162. doi: 10.3892/ol.2019.9951. Epub 2019 Jan 21.

Supplemental Content

Loading ...
Support Center